The dose-dependent reduction of cell invasion was observed in PTCL cells treated with AT56 (Fig. 3j), which was accompanied by the decreased expression of zeb1 and vimentin (Fig. 3k). The gene discussed is VIM; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.